Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 18 | 2023 | 46 | 6.280 |
Why?
|
| Factor VIII | 13 | 2023 | 32 | 4.350 |
Why?
|
| Coagulants | 7 | 2020 | 11 | 3.050 |
Why?
|
| Hemorrhage | 9 | 2023 | 81 | 3.040 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 43 | 1.370 |
Why?
|
| Antibodies, Neutralizing | 4 | 2018 | 19 | 1.040 |
Why?
|
| Isoantibodies | 3 | 2018 | 8 | 1.000 |
Why?
|
| Hemarthrosis | 6 | 2021 | 20 | 0.960 |
Why?
|
| Drug Substitution | 1 | 2020 | 4 | 0.720 |
Why?
|
| Recombinant Proteins | 6 | 2020 | 213 | 0.640 |
Why?
|
| Health Literacy | 1 | 2021 | 109 | 0.640 |
Why?
|
| Physicians | 1 | 2020 | 124 | 0.590 |
Why?
|
| Adolescent | 10 | 2021 | 2309 | 0.570 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 328 | 0.540 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 166 | 0.540 |
Why?
|
| Child | 8 | 2020 | 1421 | 0.540 |
Why?
|
| Mutation | 1 | 2018 | 354 | 0.520 |
Why?
|
| Young Adult | 9 | 2021 | 2070 | 0.460 |
Why?
|
| Time Factors | 5 | 2020 | 1491 | 0.440 |
Why?
|
| Factor VIIa | 3 | 2017 | 7 | 0.430 |
Why?
|
| Hemophilia B | 3 | 2017 | 10 | 0.430 |
Why?
|
| Humans | 25 | 2023 | 28435 | 0.420 |
Why?
|
| Fibrinolysis | 2 | 2013 | 7 | 0.390 |
Why?
|
| Male | 16 | 2021 | 15292 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 390 | 0.370 |
Why?
|
| United States | 5 | 2020 | 2200 | 0.370 |
Why?
|
| Fibrinolysin | 1 | 2011 | 1 | 0.370 |
Why?
|
| Thrombin | 1 | 2011 | 15 | 0.360 |
Why?
|
| Blood Coagulation | 1 | 2011 | 20 | 0.360 |
Why?
|
| Adult | 9 | 2020 | 8107 | 0.320 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3616 | 0.320 |
Why?
|
| Retrospective Studies | 4 | 2023 | 3612 | 0.300 |
Why?
|
| Quality of Life | 3 | 2020 | 661 | 0.270 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 988 | 0.270 |
Why?
|
| Middle Aged | 7 | 2020 | 9270 | 0.260 |
Why?
|
| Half-Life | 3 | 2023 | 12 | 0.260 |
Why?
|
| Child, Preschool | 6 | 2017 | 689 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 330 | 0.250 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1216 | 0.240 |
Why?
|
| Risk Assessment | 1 | 2017 | 677 | 0.230 |
Why?
|
| Pilot Projects | 2 | 2021 | 440 | 0.190 |
Why?
|
| Phenotype | 3 | 2018 | 313 | 0.180 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 7 | 0.180 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 21 | 0.180 |
Why?
|
| Joint Diseases | 2 | 2012 | 113 | 0.180 |
Why?
|
| Israel | 1 | 2020 | 17 | 0.170 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 45 | 0.170 |
Why?
|
| Netherlands | 1 | 2020 | 25 | 0.170 |
Why?
|
| Drug Costs | 1 | 2020 | 13 | 0.170 |
Why?
|
| Cost Savings | 1 | 2020 | 36 | 0.170 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 17 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 37 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 89 | 0.160 |
Why?
|
| Sickle Cell Trait | 1 | 2018 | 2 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 159 | 0.150 |
Why?
|
| Television | 1 | 2018 | 7 | 0.150 |
Why?
|
| South America | 1 | 2018 | 3 | 0.150 |
Why?
|
| Asia | 1 | 2018 | 10 | 0.150 |
Why?
|
| Africa | 1 | 2018 | 11 | 0.150 |
Why?
|
| Information Dissemination | 1 | 2018 | 20 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2018 | 59 | 0.150 |
Why?
|
| North America | 1 | 2018 | 43 | 0.150 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 59 | 0.150 |
Why?
|
| Europe | 1 | 2018 | 66 | 0.150 |
Why?
|
| Sports Medicine | 1 | 2018 | 37 | 0.150 |
Why?
|
| Prothrombin | 1 | 2017 | 4 | 0.140 |
Why?
|
| Athletes | 1 | 2018 | 88 | 0.140 |
Why?
|
| Social Media | 1 | 2018 | 50 | 0.140 |
Why?
|
| Anticoagulants | 2 | 2015 | 90 | 0.140 |
Why?
|
| Risk Factors | 2 | 2018 | 2408 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 492 | 0.130 |
Why?
|
| von Willebrand Factor | 1 | 2016 | 10 | 0.130 |
Why?
|
| Hematology | 1 | 2016 | 4 | 0.130 |
Why?
|
| Physicians, Women | 1 | 2016 | 17 | 0.130 |
Why?
|
| Physician Executives | 1 | 2016 | 8 | 0.130 |
Why?
|
| Career Choice | 1 | 2016 | 30 | 0.130 |
Why?
|
| Blood Coagulation Tests | 2 | 2016 | 11 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 730 | 0.120 |
Why?
|
| Leadership | 1 | 2016 | 107 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 46 | 0.120 |
Why?
|
| Infant | 3 | 2016 | 588 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 553 | 0.110 |
Why?
|
| Factor VII Deficiency | 1 | 2013 | 1 | 0.110 |
Why?
|
| Female | 6 | 2020 | 15728 | 0.100 |
Why?
|
| Factor IX | 1 | 2012 | 7 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 351 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 352 | 0.090 |
Why?
|
| Aged | 3 | 2020 | 9278 | 0.090 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 6 | 0.080 |
Why?
|
| Death, Sudden | 1 | 2009 | 7 | 0.080 |
Why?
|
| Vena Cava, Inferior | 1 | 2009 | 11 | 0.080 |
Why?
|
| Constriction, Pathologic | 1 | 2009 | 33 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 19 | 0.080 |
Why?
|
| Headache | 2 | 2017 | 34 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2017 | 63 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2017 | 267 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 98 | 0.070 |
Why?
|
| Patients | 1 | 2023 | 35 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2016 | 1926 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 1809 | 0.040 |
Why?
|
| Subtraction Technique | 1 | 2009 | 1 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 53 | 0.040 |
Why?
|
| Newspapers as Topic | 1 | 2018 | 1 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2017 | 6 | 0.040 |
Why?
|
| Dizziness | 1 | 2017 | 18 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 63 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 25 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 24 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 47 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 145 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 183 | 0.030 |
Why?
|
| Colorado | 1 | 2015 | 4 | 0.030 |
Why?
|
| Florida | 1 | 2015 | 22 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 22 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 110 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 102 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 38 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 80 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 232 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 322 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 207 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 773 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 737 | 0.030 |
Why?
|
| Synovitis | 1 | 2011 | 21 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 84 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 933 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 102 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2009 | 44 | 0.020 |
Why?
|
| Autopsy | 1 | 2009 | 343 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 1461 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 3780 | 0.010 |
Why?
|